AMVUTTRA™ (vutrisiran) is a prescription medicine given once every 3 months by a healthcare professional to treat the polyneuropathy caused by an illness called hereditary ATTR (hATTR) amyloidosis in adults.
Significant
improvement in
nerve functiona
Significant
improvement in
quality of lifeb
Dosing
once every
3 months
In an 18-month clinical study, AMVUTTRA-treated patients showed significant improvement in nerve function and quality of life at 9 months and continued to improve throughout the study, compared with those who received placebo.
- aNerve function was assessed using a scale called mNIS+7 that measured strength and sensation in the hands, feet, arms, and legs; reflexes; and blood pressure upon standing.
- bQuality of life was evaluated by the Norfolk QoL-DN questionnaire that asked patients about the severity of their polyneuropathy symptoms, how often they experienced them, and what impact they felt they had on their daily lives.